Hugel Inc operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hugel Inc with three other
companies in this sector in South Korea:
Medy Tox Inc
sales of 205.44 billion Korean Won [US$174.22 million]
of which 95%
was Finished Goods),
G-treeBNT Co Ltd
(46.36 billion Korean Won [US$39.31 million]
of which 61%
was Medicine), and
Cell Biotech Co ., Limited.
(62.54 billion Korean Won [US$53.04 million]
of which 89%
was Finished Products).
Hugel Inc reported sales of 182.39 billion Korean Won (US$154.67 million)
December of 2018.
a very small
increase of 0.2%
versus 2017, when the company's sales were 182.09 billion Korean Won.
Sales at Hugel Inc have increased during each of the previous five years
(and since 2013, sales have increased a total of 525%).